IDIBELL-Bellvitge Biomedical Research Institute

Oncology & Cancer

The complete epigenomes of the most frequent tumors mapped

A research team from the Bellvitge Biomedical Research Institute (IDIBELL) has managed to characterize the complete epigenomes of the most frequent tumors, including those of colon, lung and breast cancer. Their work, published ...

Medications

First photoactive drug for pain treatment

A team of the Institute of Neurosciences of the University of Barcelona has participated in the design of the first light-activated drug, JF-NP-26, for the treatment of pain, according to a study with animal models published ...

Oncology & Cancer

An epigenetic lesion could be responsible for acute T-cell leukemia

Researchers from the Epigenetics and Cancer Biology Program (PEBC) led by Dr. Manel Esteller at the Bellvitge Biomedical Research Institute (IDIBELL) have discovered how an epigenetic lesion can lead to T-cell acute lymphoblastic ...

Oncology & Cancer

Team unveils new TGF-beta functions in liver cancer

Recent research results from the TGF-beta and cancer research group at the Bellvitge Biomedical Research Institute (IDIBELL) provide a better understanding of the role of the TGF-beta cytokine in liver cancer. The work, published ...

Oncology & Cancer

After the epigenome: The epitranscriptome

Our genome is made up of 6,000 million pieces of DNA that combine four "flavors": A, C, G and T (Adenine, Cytosine, Guanine and Thymine). It is our Alphabet. But to this base we must add some regulation, just like the spelling ...

page 6 from 14